The Digital Medicine Society (DiMe) announced today a new collaboration with Acclinate, Amgen, GSK, Lightship, Medable, Rubix LS, Sage Bionetworks, Savvy Cooperative, and THREAD Research to drive inclusion in digital clinical trials. The initiative aims to provide the tools and framework necessary to successfully integrate diverse perspectives during the planning process for trials that include a technology device for participation.
Key Takeaways and Learnings Underrepresentation slows recruitment, increases dropout risk, and weakens data reliability. Proactive inclusion strategie...
Key Takeaways and Learnings Traditional “one-size-fits-all” recruitment fails to address the barriers and concerns of underrepresented communities. Or...
Key Takeaways and Learnings Over the past few years, FDA diversity guidance has recommended early, structured inclusion planning. Despite shifting pol...
In healthcare, we often hear terms like community outreach and community engagement used interchangeably. They sound similar—both involve connecting w...
Key Takeaways and Learnings Building trust in clinical trials requires early, sustained community engagement—not just recruitment outreach. Historical...
Key Takeaways and Learnings Health equity solutions must be rooted in community-informed design, not top-down assumptions. Building trust requires ong...
Key Takeaways and Learnings The recent FDA diversity in clinical trials guidance emphasizes how sponsors plan on reaching specific representation goal...
Key Takeaways and Learnings Representation is so much more than just showing up. Performative inclusion weakens trust and risks perpetuating dispariti...
